摘要
阿尔茨海默症(AD)即老年痴呆症,是以老年斑和神经元纤维缠结为主要病理特征的神经退行性疾病。AD的发病机制是多种发病因素、多种通路和分子机制的相互参与,例如信号异常、炎症和免疫系统、脂质转运、细胞内吞作用、细胞凋亡、氧化损伤和应激反应、tau病理学、神经元和突触的损失、能量代谢等。目前没有一种AD治疗方法能从根本上停止其病理的退行性改变,但仍有多种治疗策略。我们从生物标志物、遗传、神经影像、药物治疗、β淀粉样蛋白免疫治疗方面,对阿尔茨海默症的治疗研究进展进行了简要综述。
Alzheimer＇s disease（AD） is a progressive neurodegenerative disorder characterized by two pathological hallmarks： senile plaques and neurofihrillary tangles. AD is related to muhiple interactive systems, pathways and molecular mechanisms such as aberrant signaling, inflammation and immune system, lipid transport, endocytosis, apoptosis, oxidative damage and response to stress, tau pathology, neuron and synapse loss, energy metabolism. Cur- rently approved treatments, including the aeetylcholinesterase inhibitors（AChEl） donepezil, galantamine, rivastig- mine, and the N-methyl-D-aspartate（NMDA） antagonist memantine, do not halt the progression of the disease, and have provided marginal therapeutic benefits. However, there are still many treatment strategies. In this article we introduced the progress in the treatment of AD from many aspects, such as biomarkers, genetic, neuroimaging, drug treatment, and amyloid 13 peptide immunotherapy.
出处
《生物技术通讯》
CAS
2013年第2期276-279,共4页
Letters in Biotechnology
基金
重大新药创制科技重大专项"十二五"实施计划(2011ZX09401-023)
